DOV
63
-6
GD
64
2
PEP
32
-3
AMGN
38
4
PNW
55
2
MPC
36
-2
OKE
65
3
GWW
67
2
UNM
63
-2
ES
45
-4
VRSK
32
2
EXR
26
2
C
84
2
TJX
55
2
HIG
70
2
DOW
42
2
ROST
68
-3
ZTS
25
4
YUM
58
2
FTI
64
-5
DOV
63
-6
GD
64
2
PEP
32
-3
AMGN
38
4
PNW
55
2
MPC
36
-2
OKE
65
3
GWW
67
2
UNM
63
-2
ES
45
-4
VRSK
32
2
EXR
26
2
C
84
2
TJX
55
2
HIG
70
2
DOW
42
2
ROST
68
-3
ZTS
25
4
YUM
58
2
FTI
64
-5
Financhill
Back

Carisma Therapeutics, Inc. 10K Form

Sell
20

CARM
Carisma Therapeutics, Inc.

Last Price:
$0.04
Seasonality Move:
-21.27%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CARM News And Ratings

See the #1 stock for the next 7 days that we like better than CARM

CARM Financial Statistics

Sales & Book Value

Annual Sales: $19.6M
Cash Flow: $1.9M
Price / Cash Flow: 0
Annual Sales: $-0.02
Price / Book: 123.48

Profitability

EPS (TTM): 0.18810
Net Income (TTM): $8M
Gross Margin: $16.3M
Return on Equity: -437.23%
Return on Assets: 40.2%

Carisma Therapeutics, Inc. Earnings Forecast

Key Carisma Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 14 years for CARM is 82.92%.
  • The Selling, General & Administrative Expenses for CARM have been equal to 112.76% of Gross Profit Margin.
  • The Research & Development expenses have been 303.96% of Revenue.
  • The Net Earning history of CARM is -308.05% of Total Revenues.
  • Per Share Earnings over the last 14 years have been positive in 8 years.

Carisma Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Biotechnology
Sector: Health Care
Current Symbol: CARM
Website: carismatx.com

Debt

Debt-to-Equity Ratio: -0.88
Current Ratio: 0.86
Quick Ratio: 0.41

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CARM Technical Analysis vs Fundamental Analysis

Sell
20
Carisma Therapeutics, Inc. (CARM) is a Sell

Is Carisma Therapeutics, Inc. a Buy or a Sell?